7% CER growth, 19-23% EBIT beat and now net cash positive. Company being reshaped, pipeline strengthening. Attractive 12% FCF yield, company becoming stronger.

16 May 2024
Intriguing company transformation in progress

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Intriguing company transformation in progress
H. Lundbeck A/S Class B (HLUN.B:CSE) | 0 0 0.0%
- Published:
16 May 2024 -
Author:
ABGSC Healthcare Research | Morten Larsen -
Pages:
11 -
7% CER growth, 19-23% EBIT beat and now net cash positive. Company being reshaped, pipeline strengthening. Attractive 12% FCF yield, company becoming stronger.